{"name":"EpicentRx, Inc.","slug":"epicentrx-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Cisplatin/carboplatin plus etoposide","genericName":"Cisplatin/carboplatin plus etoposide","slug":"cisplatin-carboplatin-plus-etoposide","indication":"Small cell lung cancer","status":"phase_3"},{"name":"RRx-001 + eLOOP Device","genericName":"RRx-001 + eLOOP Device","slug":"rrx-001-eloop-device","indication":"Advanced solid tumors (Phase 3 development)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AdAPT-001","genericName":"AdAPT-001","slug":"adapt-001","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"AdAPT-001","genericName":"AdAPT-001","slug":"adapt-001","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Cisplatin/carboplatin plus etoposide","genericName":"Cisplatin/carboplatin plus etoposide","slug":"cisplatin-carboplatin-plus-etoposide","phase":"phase_3","mechanism":"This combination uses platinum-based chemotherapy agents (cisplatin or carboplatin) to cross-link DNA, combined with etoposide, a topoisomerase II inhibitor that prevents DNA unwinding and repair.","indications":["Small cell lung cancer","Germ cell tumors","Lymphomas"],"catalyst":""},{"name":"RRx-001 + eLOOP Device","genericName":"RRx-001 + eLOOP Device","slug":"rrx-001-eloop-device","phase":"phase_3","mechanism":"RRx-001 is a small-molecule immunotherapeutic that works synergistically with the eLOOP device to enhance immune activation and tumor cell death through modulation of immune checkpoints and metabolic pathways.","indications":["Advanced solid tumors (Phase 3 development)","Potentially checkpoint inhibitor-resistant cancers"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxOWnU3YnJCYzNuV0Y1RUFWQXpUYlFDTXhGa1hlMnhGRjAyRy01WXNJc05KSmd3RUVKZmV0aUxXWjVPbkV2dkhwb0s1NFdOWTRKSUVvYW8zdFNGSGJQSG5NMzFVQnB3WC12dS1ZQ3VPQnJ0a3pkVzdfTUlaMmV1bEp4VVJ1YS1QTmRBYlpJOGNYQ0c0M3VFcmZyeVhLTnJQcENYcmdkTHNWSmZiam45YlBwRVI0eHhJNkJPX0ZjdE1mZ2hOX0c5dVRNeUZtOU1LUzNpQjJhZ2NwNmpTQlBoSlh0VmpxbDBaWkZQX05YVmlvMFRzZXc2bnBRd2RrS3hNZFphTVhkT2hCc3BMUlliNHd3bXl3ZnJXa3M5NEFqR1ZNdHlERG_SAaMCQVVfeXFMTlp1N2JyQmMzbldGNUVBVkF6VGJRQ014RmtYZTJ4RkYwMkctNVlzSXNOSkpnd0VFSmZldGlMV1o1T25FdnZIcG9LNTRXTlk0SklFb2FvM3RTRkhiUEhuTTMxVUJwd1gtdnUtWUN1T0JydGt6ZFc3X01JWjJldWxKeFVSdWEtUE5kQWJaSThjWENHNDN1RXJmcnlYS05yUHBDWHJnZExzVkpmYmpuOWJQcEVSNHh4STZCT19GY3RNZmdoTl9HOXVUTXlGbTlNS1MzaUIyYWdjcDZqU0JQaEpYdFZqcWwwWlpGUF9OWFZpbzBUc2V3Nm5wUXdka0t4TWRaYU1YZE9oQnNwTFJZYjR3d215d2ZyV2tzOTRBakdWTXR5RERv?oc=5","date":"2026-02-04","type":"trial","source":"Bolsamania","summary":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Bolsamania","headline":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxPV1M3NXRQVDYwUnJSS2F0Nlh5LVRJMFlFQjdOMnc3ODczRXVYbmxVRXZCLVFJMDdCRU01ZHZmRkZjcGY1VjlFQWd2WFBuTFNoZ2ZJRTl0Rk9IcTNmUjZyaDE0ZTBHTFJDRFlYYURnT0xRWUlzWUxwX0VoWmZqMThBUVdVS0NnbHAwN2pjRkV2TVJtVS1GWWI4SF9oYnVlUGUya2NjOHpncXBjN0ZpSjV2dk1ST0VYQWhWNTNIdkdLYmU3OEk3UGR3WjNyaFk4aWtfaHF5SUtSZHFJRUdYMW9kMVl5MUVrVU52RVFlRUdQOVE?oc=5","date":"2025-01-29","type":"trial","source":"PR Newswire","summary":"Endometriosis Clinical Trial Pipeline Gains Momentum as 15+ Key Companies at the Forefront | DelveInsight - PR Newswire","headline":"Endometriosis Clinical Trial Pipeline Gains Momentum as 15+ Key Companies at the Forefront | DelveInsight","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxQektGbzNsN09ncEhPbnlJM3gtbTVkUE51QTZ1VmQycnk3ZTlkQ3RYb1p6VUV2eG5nQjZBN2NEcEJGZkpxdlJZS1M1WURvRmlvVmg3b2FUYTFUZEVZSnZ0OG95S0phcW9oc19sVzV0NUthZEVvZ0dPbnN4c2lxMXk2VlRxN0s5V3IxR1pObGxkR2p0c0wzU0RaQndBeTd6TWZJLU9NdnMwUzdQYW9ZZWtPNVpOM3FfbzlmOFlodml6ZVg3X0VKbHVIU2NZamtFMms2cUd0NUxrUFRWVTBYQVR1eG9ZVjlTcXNZLVgyNUpXVnNaeXNtRzF1WHhOSHpSb1NOa3E3TThyNG94dGhuLWQwYlVFZWQ2UkRybXd6SHZVbFdfZzhpbG1HYTRCOWdzUVREUXQ3Zw?oc=5","date":"2024-12-05","type":"regulatory","source":"PR Newswire","summary":"EpicentRx's Oncolytic Virus-delivered TGFβ Inhibitor, AdAPT-001, Receives FDA Fast Track Designation for Recurrent or Refractory Soft Tissue Sarcoma Treatment - PR Newswire","headline":"EpicentRx's Oncolytic Virus-delivered TGFβ Inhibitor, AdAPT-001, Receives FDA Fast Track Designation for Recurrent or Re","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxNR3JCQnhRWFJKakk0Ykwxd25Za2xkR2lvY1ZPbGNUR29BaDZiaHZ5TWRZbmxUUm9RaXNPWFNjaFduVUw5NHBZRmZWQ01KYnUwNlVlRzg3UFVZcWJ4eFpzNHk1VGZLNDd4OWwzUllQRkIyZFNsVzB5UDBNd3Q3OGFMQllCR2NDczdtaXhETmhhM0swQ2oxT1NRRnlvdkRQbzRGLWFJX3BqTXRXcHQya3ctdFJEYlc0YlAwdFo0bW1TMFNTQUhSb01scmI2SFYwN3RISDhRUU9yazBLWklLMU9nbEJINGdaa3QtdTh3d0dYdHVnY3R1b2FEZDFWcGk2YkdqX25yOVVNUC1xOVRVWDVKcl80NGgwc0ZwZW9MLUJLYjFmWkl6T1NOT1hXQ1h4eVlNNTVLVU9pWDB4bFBLVUdiSEMzT0wyZ0ZVMERyTmdYanlXWGhwbGc?oc=5","date":"2024-11-13","type":"trial","source":"GlobeNewswire","summary":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears - GlobeNewswire","headline":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQV2JiTkwydlZ6c2FNV1hiTmwyZ3NtemctN3A2bWlnY1ZkWHhSek1GRl9wOWdyUmswc0pVd3NTRDJ6b2FKaG9pSFRsVlVxYzJ2R2tSM0RwWVJkMVdIOWtsWDBCQW42eF80dTRyOU5rMER6MUQxMzYxMEI0QkVNN2hqMUlvLTQwYXVKTVZmcVlPRFlRYjBMMGFSSXU2SUVFU3Y1MGZCeWlUMU0zZw?oc=5","date":"2024-05-20","type":"pipeline","source":"Citeline News & Insights","summary":"Will Actinium Be Big Pharma’s Next Radiopharmaceuticals Acquisition? - Citeline News & Insights","headline":"Will Actinium Be Big Pharma’s Next Radiopharmaceuticals Acquisition? - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQU1hsdjdCSDZJcDVybXl4Vmw5R1U3RmVENlpLUmVPTDZlN3dYUEdFcWNIVi1PbXhPWTkxdGZMZHB3TzNKU0NoQ2wtalVDdk1PZzg5aVZtRU1ZTW5qUWJmY2xIOHlaRTQxczNsNU1CWk5SNV8xaFJxdDRxVDJyN1ZxVDV0ZTJ1WFQzZzY4WEQ5cmE3RmZaSmJhb2w3QmtMemNKal82dnM2Z0tiQ1ZwTTZhTnpZdDVwekdqYVFsN2x4dG4ydnFXUk5hSlYydU8wSXp2R0lnOHRhWENGb0pLYVdKVjBtVHpuUGkwcjln?oc=5","date":"2024-04-03","type":"regulatory","source":"Mayer Brown","summary":"A Matter Of Propriety: Delaware Courts Reject Books-and-Records Demand Driven by Ulterior Motive - Mayer Brown","headline":"A Matter Of Propriety: Delaware Courts Reject Books-and-Records Demand Driven by Ulterior Motive","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNaFFSM1lKSy03R1FYZ3hhR3VhMHhHVmNBb2RJQkJUb0tCVU5SdE5nVmpZX0c4NVkza3VmWUgxRUdIYnVWVEtPaFJvM2tBVGlNdVRYNTd5alpYWDlvTGhPQUpZNkdET2dZV0RiVElDX3pGLWpWTzZvd01XTkZEcW53ZlFhREJqeXpMTjEyZXdnQTdmcmxpOTdweXRfMlBOS040dFBxRTRhVmpkNmcwblRYVThMVTdvOE55WExyN2dFTFN6UVNYb3A4bGxfQ2FfZWhKQ3Q2c012UHZQRnpHaWllRWo5XzNiRHNZUW4w?oc=5","date":"2023-11-06","type":"trial","source":"PR Newswire","summary":"EpicentRx To Present Nibrozetone (RRx-001) Data on Parkinson's Disease and ALS/MND at Neuroscience 2023 - PR Newswire","headline":"EpicentRx To Present Nibrozetone (RRx-001) Data on Parkinson's Disease and ALS/MND at Neuroscience 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOMUZCVFl0WWEyODluWUdNSzI1QWptbTJVQzgyR1o0TmhVQnJrTDdhWDk5eUxXc2ltMVRncUJhMmtvci1Cdjl1ZV9SZzBVVS1oUHBlVm1GT09oMG5YZUpuSVhyM09PZmthbkFDZzN2X2ZJRDYzMEV2X3pDWndQTXlGNjkteGhBNXlIcHlIYlhmRmhNQQ?oc=5","date":"2022-11-23","type":"pipeline","source":"Yahoo Finance","summary":"Extremely Robust Brain Metastases Pipeline Featuring 45+ Companies Expected to Change the Pace of the Brain Metastases Treatment | DelveInsight - Yahoo Finance","headline":"Extremely Robust Brain Metastases Pipeline Featuring 45+ Companies Expected to Change the Pace of the Brain Metastases T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPM1AwQWxrcHl2WjNLYnZid05NX3B5YjM4czEyS0tpNURsdXRhZEZQUVR2Y0pEZ3lPaHRSV3RlaUl2WDlXT09YaElzc1V0QmYzaEY1cEZkZHhyaXlONGpEQTAzSTlGV2MyaVhOMF9IQ2JpdWlwNlRMSXF2RnV0eVhkNmEtMmRGRjl6QmdzaUprS1NHZm9scXlndWhoRm9kalRPMmRPcWJKZGlUVVRBdlFPc0pVUUdVcmQteFhIeWpfWkFEdFg0Q2NfQ2FYOEJ3QjE2dE9yMjFuTGI5Tl9weXJXOEZmblJVRmpCRGgtdl9R?oc=5","date":"2020-07-01","type":"pipeline","source":"PR Newswire","summary":"EpicentRx Inc. and SciClone Pharmaceuticals Establish Licensing Agreement for RRx-001 in Greater China - PR Newswire","headline":"EpicentRx Inc. and SciClone Pharmaceuticals Establish Licensing Agreement for RRx-001 in Greater China","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":1,"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}